Increased platelet activation in young patients with prehypertension

Clinical and Experimental Hypertension

Volumn 33, Issue 6, 2011, Pages 381-387

  Yuksel, Cagdas ^a   Celik, Turgay ^b   Demirkol, Sait ^b   Celik, Murat ^b   Bugan, Baris ^b   Iyisoy, Atila ^b   Yaman, Halil ^b  

^a Sarikamis Army District Hospital Turkey   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Mean platelet volume; Prehypertension; SP selectin

Indexed keywords

GLUCOSE; LIPID; SELECTIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; MALE; PREHYPERTENSION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME;

ADULT; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET COUNT; PREHYPERTENSION; RISK FACTORS;

EID: 80053245194     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.549263     Document Type: Article

References (37)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 ;360: 1903-1913. (Pubitemid 35472129)
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
3. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006;48:833-838. (Pubitemid 44175741)
4. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119:133-141. (Pubitemid 43151479)
5. Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in pre-diabetes and prehypertension: New findings and their research and clinical implications. Diabetes Care 2007; 30:2708-2715.
6. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765-774. (Pubitemid 20106689)
7. Lee AJ. The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 1997;11:767-776. (Pubitemid 28043333)
8. Celik T, Iyisoy A, Kursaklioglu H, Turhan H, Cagdas Yuksel U, Kilic S, Kutsi Kabul H, Genc C. Impaired aortic elastic properties in young patients with prehypertension. Blood Press Monit 2006;11:251-255. (Pubitemid 44319044)
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
10. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000;101:218-220. (Pubitemid 30054143)
11. Blann AD, Naqvi T,Waite M, McCollum CN. vonWillebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993;7:107-111. (Pubitemid 23138184)
12. Fogari R, Zoppi A, Marasi G, Vanasia A, Villa G. Associations between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J Cardiovasc Risk 1994;1: 341-345.
13. Andrioli G, Ortolani R, Fontana L, Gaino S, Bellavite P, Lechi C, Minuz P, Manzato F, Tridente G, Lechi A. Study of platelet adhesion in patients with uncomplicated hypertension. J Hypertens 1996;14:1215-1221. (Pubitemid 26343501)
14. Mehta JL, Lopez LM, Chen L, Cox OE. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 1994;74:901-905. (Pubitemid 24340312)
15. Nityanand S, Pande I, Bajpai VK, Singh L, Chandra M, Singh BN. Platelets in essential hypertension. Thromb Res 1993;72:447-454. (Pubitemid 23345334)
16. Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004;44:415-422. (Pubitemid 38950604)
17. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 1969;48:1083-1087.
18. Kamath S, Blann AD, Lip GY. Platelet activation: Assessment and quantification. Eur Heart J 2001;22:1561-1571. (Pubitemid 32801301)
19. Bath PM, Butterworth RJ. Platelet size: Measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996;7:157-161. (Pubitemid 26167943)
20. Papanas N, Symeonidis G,Maltezos E,Mavridis G, Karavageli E, Vosnakidis T, Lakasas G. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15: 475-478. (Pubitemid 39656855)
21. Nadar S, Blann AD, Lip GY. Platelet morphology and plasma indices of platelet activation in essential hypertension: Effects of amlodipine-based antihypertensive therapy. Ann Med 2004;36:552-557. (Pubitemid 39490964)
22. Pathansali R, Smith N, Bath P. Altered megakaryocyteplatelet haemostatic axis in hypercholesterolaemia. Platelets 2001;12:292-297. (Pubitemid 32730516)
23. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59:981-982.
24. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002;117: 399-404. (Pubitemid 34451156)
25. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338: 1409-1411.
26. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999;79:181-213. (Pubitemid 29056952)
27. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989;73:1109-1112. (Pubitemid 19107409)
28. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-886. (Pubitemid 16256841)
29. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002;40: 61-66. (Pubitemid 34755980)
30. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103: 491-495. (Pubitemid 32116231)
31. Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: Implications for atherogenesis? A preliminary report. J Hypertens 1995;13: 1674-1678. (Pubitemid 26015796)
32. Shimomura H, Ogawa H, Arai H, Moriyama Y, Takazoe K, Hirai N, Kaikita K, Hirashima O, Misumi K, Soejima H, Nishiyama K, Yasue H. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol 1998;81:397-400. (Pubitemid 28099527)
33. Davi G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998;97:953-957. (Pubitemid 28125466)
34. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. Should we treat prehypertension? Blood Press 2009;18:298-299.
35. Kiely AE, Kwatra SG, Kwatra MM. Treating prehypertension: Medically sound and economically viable. Blood Press 2009;18:300-303.
36. Schulman IH, Zhou MS. Vascular insulin resistance: A potential link between cardiovascular and metabolic diseases. Curr Hypertens Rep 2009;11:48-55.
37. Bath PM, Butterworth RJ. Platelet size: Measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996;7:157-161. (Pubitemid 26167943)